Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

A large twin study found that adverse childhood experiences increase the risk of developing treatment-resistant depression.

Alto Neuroscience, Inc. (NYSE: ANRO) shares fell first thing Tuesday. The company, a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today ...

Is brain imaging overlooking the truth? Research shows that "weak" brain connections predict behavior as well as top signals, ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Young women with depression are more likely to have lower levels of taurine in their hippocampus than healthy controls. The corresponding study was published in Biological Psychiatry. Between 2013 and ...

A new study found that depression may increase the risk of menstrual pain through factors like sleep disturbances. The findings suggest that treating sleep and mental health issues may help relieve ...

Flow Neuroscience, a small Swedish company treating depression with brain-stimulating headsets, released early data on Monday showing that its device relieved depressive symptoms in clinical trials.

In January, Reunion completed its Phase 1 placebo-controlled study. Reunion’s other pipeline program is the RE200 series, which are novel molecules structurally similar to classic psychedelics. Get ...

Alto Neuroscience is focused on developing precision medicine for mental health. On Tuesday, the company announced some promising signs for its treatment ALTO-100. The drug is geared toward treating a ...

AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the ...